Witryna9 sty 2024 · An increasing number of high-risk or complex lesions are being treated with PCI and we hypothesize that the impact of IVUS in these complex lesions will be of increased importance in reducing clinical adverse events while remaining cost effective. ... (IMPROVE) trial: Study design and rationale. Am Heart J. 2024 Oct;228:65-71. doi: … Witryna21 lis 2024 · IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer (IMPROVE-IT) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.
Benefit of Adding Ezetimibe to Statin Therapy on ... - Circulation
WitrynaIMPROVE-IT (TIMI 40) – TIMI STUDY GROUP IMPROVE-IT (TIMI 40) IMPROVE-IT (TIMI 40) determined whether the addition of ezetimibe … Witryna20 gru 2024 · Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008; 156:826–832. doi: 10.1016/j.ahj.2008.07.023. Crossref … custom personal checks with free shipping
DANAMI-3 PRIMULTI - Wiki Journal Club
Witryna12 lut 2024 · IMPROVE-IT, a contemporary, large, and well-designed trial, unequivocally demonstrated reduction in CV outcomes with ezetimibe when added to statin therapy. … WitrynaExpert opinion: The results from IMPROVE-IT revalidated the concept that low-density lipoprotein cholesterol (LDL-C) levels are a clinically relevant treatment goal. This trial also suggested that further decrease of LDL-C levels (53 vs. 70 mg/dl; 1.4 vs. 1.8 mmol/l) was more beneficial in lowering CV events. Witrynarin Efficacy International Trial (IMPROVE-IT) is provided in the Supplementary Appendix, available at NEJM.org. This article was published on June 3, 2015, at … chauvet 512 dmx download